On July 17, HCA Healthcare fell 3.03% in regular trading, trading at $374.31/share, with turnover of $257 million. The decline came as selling pressure re-emerged following the exhaustion of a two-day oversold bounce.

On the news front, the company had previously cut its full-year adjusted diluted EPS guidance, triggering an initial plunge of over 8%. While a subsequent disclosure of expected Q2 revenue of approximately $20.23 billion — well above the market consensus of $19.47 billion — and a $4 billion net benefit from Medicaid supplemental payment programs fueled a brief recovery, that rebound momentum has now dissipated. Multiple Wall Street banks have recently cut their price targets: Mizuho lowered its target from $585 to $525, Stephens from $500 to $480, and Barclays downgraded the stock to equal weight with a target of $427. The FactSet consensus mean target has declined from approximately $546 at the start of the year to around $490.85. The broader Health Care Facilities sector also remained under pressure, with Tenet Healthcare down 0.82% and Universal Health Services down 1.49%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)